Trial name or title |
The effectiveness and safety of vertebroplasty for osteoporotic vertebral compression fractures. A double blind, prospective, randomised, controlled study |
Methods |
Randomised controlled trial, participant blinded |
Participants |
Planned sample size = 164 Inclusion criteria
More than or equal to 50 years of age
Back pain (more than or equal to 4 on 0 to 10 scale)
1 to 3 recent painful osteoporotic vertebral fractures (minimum 15% loss of height, oedema or fracture line within vertebral body) from T5 through L5
Decreased bone density T‐score less than or equal to ‐1.
Exclusion criteria
More than 3 recent spine fractures, pedicle fracture, or previous vertebroplasty or kyphoplasty and neurological deficit, radicular pain, radicular and/or myelum compression syndrome or canal narrowing
More than 90% osteoporotic vertebral collapse, fracture through/destruction of posterior wall, retropulsed bony fragment or bone fragments impinging on spinal cord
Spinal or systemic infections
Vertebral fractures resulting from primary bone tumours osteoblastic metastases or current malignancy
Severe cardio‐pulmonary condition
Dementia
Untreatable coagulopathy or uninterruptible anticoagulation therapy
Allergies to materials used in vertebroplasty or kyphoplasty materials and contraindications to MRI
Unable to give informed consent
|
Interventions |
Vertebroplasty
Three weeks period of bed rest, wearing a rigid hyperextension suspension brace, with positive three‐point suspension (sternal, suprapubic and thoracolumbar)
|
Outcomes |
Duration of follow‐up to 24 months Primary outcome
VAS score (10 cm scale ‐ 0 (no pain) to 10 (worst pain ever)
Secondary outcomes
RMDQ
ODI (version 2.0)
Assessment of Quality of life (AQoL)
Utility score (Health‐related questionnaire)
Incidence of new fractures (plain film examination of the thoracic and lumbosacral spine at 1, 3, 6, 12 and 24 months)
|
Starting date |
Not specified |
Contact information |
Principal Investigator: Umile Giuseppe Longo, MD, Italy Phone: +39 06 22 54 11 E‐mail: g.longo@unicampus.it |
Notes |
Unclear if registered in a trial registry Primary sponsor: Not specified Status of trial unknown |